source
- ArriVent shares tumble as lung cancer trial of furmonertinib misses primary goalArriVent BioPharma reported that its late-stage study of furmonertinib in patients with EGFR exon 20 insertion-mutated non-small cell lung cancer did not achieve its primary endpoint. The trial, w…
- AstraZeneca launches $1 billion R&D hub in Boston’s Kendall SquareAstraZeneca opened a new research and development site in Kendall Square, Boston, marking a $1 billion investment in the U.S. biotech corridor. The Boston location underscores the company’s commit…